|
|
 Previous Article | Table of Contents | Next Article 
Altered Tumor Growth and Metastasis of a T-Cell Lymphoma in Timp-1 Transgenic Mice
Achim Krüger,
Jimmie E. Fata, and
Rama Khokha
From the Departments of Oncology and Biochemistry, University of Western Ontario, London Regional Cancer Center, London, Ontario, Canada.
The concept of tumor suppression by tissue inhibitor of metalloproteinases (TIMPs) has evolved primarily from studies of genetically modulated tumor cells. The next step is to focus on the host and assess the protective potential of host TIMP-1 on primary tumor growth and metastasis. We generated two transgenic mouse lines with altered Timp-1 expression in skin and liver: one overexpressed Timp-1 (Timp-1high), and the other had antisense RNA-mediated Timp-1 reduction (Timp-1low). ESbL-lacZ T-lymphoma cells provided the tumor challenge, as they form primary tumors upon intradermal injection with spontaneous metastasis to liver. Metastases were examined in X-Gal-stained whole-organ mounts. Timp-1 overexpression inhibited intradermal tumor growth and spontaneous metastasis, leading to prolonged survival of the mice. The opposite effects occurred in Timp-1low mice, leading to shorter host survival. Experimental metastasis assays showed that Timp-1-compromised livers in Timp-1low mice showed at least a doubling of metastatic foci and numerous additional micrometastases, indicative of increased host susceptibility. However, Timp-1high mouse livers showed an unaltered metastatic load in the experimental metastasis assay. In conclusion, these data demonstrate that Timp-1 levels within a tissue predetermine the development and progression of T-cell lymphoma.
Blood, Vol. 90 No. 5 (September 1), 1997:
pp. 1993-2000
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Kopitz, M. Gerg, O. R. Bandapalli, D. Ister, C. J. Pennington, S. Hauser, C. Flechsig, H.-W. Krell, D. Antolovic, K. Brew, et al.
Tissue Inhibitor of Metalloproteinases-1 Promotes Liver Metastasis by Induction of Hepatocyte Growth Factor Signaling
Cancer Res.,
September 15, 2007;
67(18):
8615 - 8623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ruokolainen, P. Paakko, and T. Turpeenniemi-Hujanen
Tissue Inhibitor of Matrix Metalloproteinase-1 Is Prognostic in Head and Neck Squamous Cell Carcinoma: Comparison of the Circulating and Tissue Immunoreactive Protein
Clin. Cancer Res.,
May 1, 2005;
11(9):
3257 - 3264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Lai, G. Z. Rassidakis, L. J. Medeiros, L. Ramdas, A. H. Goy, C. Cutler, Y. Fujio, K. Kunisada, H. M. Amin, and F. Gilles
Signal Transducer and Activator of Transcription-3 Activation Contributes to High Tissue Inhibitor of Metalloproteinase-1 Expression in Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma
Am. J. Pathol.,
June 1, 2004;
164(6):
2251 - 2258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Arlt, C. Kopitz, C. Pennington, K. L. M. Watson, H.-W. Krell, W. Bode, B. Gansbacher, R. Khokha, D. R. Edwards, and A. Kruger
Increase in Gelatinase-specificity of Matrix Metalloproteinase Inhibitors Correlates with Antimetastatic Efficacy in a T-Cell Lymphoma Model
Cancer Res.,
October 1, 2002;
62(19):
5543 - 5550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cianfrocca, T. P. Cooley, J. Y. Lee, M. A. Rudek, D. T. Scadden, L. Ratner, J. M. Pluda, W. D. Figg, S. E. Krown, and B. J. Dezube
Matrix Metalloproteinase Inhibitor COL-3 in the Treatment of AIDS-Related Kaposi's Sarcoma: A Phase I AIDS Malignancy Consortium Study
J. Clin. Oncol.,
January 1, 2002;
20(1):
153 - 159.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Oelmann, H. Herbst, M. Zuhlsdorf, O. Albrecht, A. Nolte, C. Schmitmann, O. Manzke, V. Diehl, H. Stein, and W. E. Berdel
Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells
Blood,
January 1, 2002;
99(1):
258 - 267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T. Ho, E. B. Voura, P. D. Soloway, K. L. M. Watson, and R. Khokha
MMP Inhibitors Augment Fibroblast Adhesion through Stabilization of Focal Adhesion Contacts and Up-regulation of Cadherin Function
J. Biol. Chem.,
October 19, 2001;
276(43):
40215 - 40224.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Guedez, A. J. McMarlin, D. W. Kingma, T. A. Bennett, M. Stetler-Stevenson, and W. G. Stetler-Stevenson
Tissue Inhibitor of Metalloproteinase-1 Alters the Tumorigenicity of Burkitt's Lymphoma via Divergent Effects on Tumor Growth and Angiogenesis
Am. J. Pathol.,
April 1, 2001;
158(4):
1207 - 1215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Krüger, R. Soeltl, I. Sopov, C. Kopitz, M. Arlt, V. Magdolen, N. Harbeck, B. Gänsbacher, and M. Schmitt
Hydroxamate-Type Matrix Metalloproteinase Inhibitor Batimastat Promotes Liver Metastasis
Cancer Res.,
February 1, 2001;
61(4):
1272 - 1275.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Lalancette, F. Aoudjit, E. F. Potworowski, and Y. St-Pierre
Resistance of ICAM-1-deficient mice to metastasis overcome by increased aggressiveness of lymphoma cells
Blood,
January 1, 2000;
95(1):
314 - 319.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Martin, J. L. Fowlkes, B. Babic, and R. Khokha
Insulin-like Growth Factor II Signaling in Neoplastic Proliferation Is Blocked by Transgenic Expression of the Metalloproteinase Inhibitor Timp-1
J. Cell Biol.,
August 23, 1999;
146(4):
881 - 892.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ries, F. Loher, C. Zang, M. G. Ismair, and P. E. Petrides
Matrix Metalloproteinase Production by Bone Marrow Mononuclear Cells from Normal Individuals and Patients with Acute and Chronic Myeloid Leukemia or Myelodysplastic Syndromes
Clin. Cancer Res.,
May 1, 1999;
5(5):
1115 - 1124.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
